Evotec

We are thrilled to announce our contributions to the agenda of next week's 𝗖𝗲𝗹𝗹 & 𝗚𝗲𝗻𝗲 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 𝗼𝗻 𝘁𝗵𝗲 𝗠𝗲𝗱 in Rome. Bernd Muehlenweg, SVP, Head of Global Business Development, Cell Therapy, will speak in the following two sessions: 𝗖𝗼𝗺𝗽𝗮𝗻𝘆 𝗣𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻 Date and Time: Tuesday, 15 April at 5:00pm CET Location: Salone dei Cavalieri, Section 2 Showcase of Evotec's activities and advancements in the cell therapy space. 𝗦𝗰𝗶𝗲𝗻𝗰𝗲 𝗦𝗹𝗮𝗺 - Diabetes: Cell and Tissue Therapy Approaches to Provide Durable Therapeutic Solutions Date and Time: Wednesday, 16 April at 1:45pm CET Location: Salone dei Cavalieri, Section 3&4 Bernd is joined by Vlad Seitan, CSO Laverock Therapeutics, and Harald Stover, Ph.D., Founder and CEO, Allarta Life Science; Professor of Chemistry and Chemical Biology, McMaster University, to discuss novel approaches for diabetes treatment. The session will be moderated by Eytan Abraham, CCO and CTO, Minaris Regnerative Medicine 𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲 𝗮𝗻𝗱 𝗿𝗲𝗮𝗰𝗵 𝗼𝘂𝘁 𝗶𝗳 𝘆𝗼𝘂 𝘄𝗼𝘂𝗹𝗱 𝗹𝗶𝗸𝗲 𝘁𝗼 𝗺𝗲𝗲𝘁 𝘂𝘀 𝗶𝗻 𝗥𝗼𝗺𝗲- https://hubs.ly/Q03g4crq0 #celltherapy #CGMed25 #iPSC

Michela Gabaldo, our VP, ATMP Global Regulatory Affairs is holding the key note lecture in today's digital event from AFI's (Associazione Farmaceutici Industria) on the evolution of regulation for advanced therapies. In her presentation, “From Bench to Bedside: navigating ATMP complex and evolving regulatory framework interplays”, Michela explains how the development of cell therapies could be optimized and accelerated through the navigation of the complex and multilayer regulatory landscape of these promising evolving field of therapeutics. She will further lay out the interplay of the different legislative frameworks and their relevancy for ATMP developers. Find out more about the event through AFI - ASSOCIAZIONE FARMACEUTICI INDUSTRIA and reach out to us if you are seeking regulatory solutions for your ATMP projects. info@evotec.com

Proud Moment for Evotec Italy! Evotec Named One of LinkedIn’s Top Companies in Italy 2025! We are thrilled to share that Evotec has been named one of LinkedIn’s Top Companies in Italy for 2025! This recognition highlights companies that empower their people, foster growth, and create meaningful opportunities for long-term success—and we couldn’t be prouder to see our commitment to people and innovation acknowledged on such a platform. A heartfelt thank you to all our colleagues in Verona and Modena — this achievement is yours. Your dedication, passion, and daily contributions make Evotec not just a great company, but a great place to grow and thrive. Read more on LinkedIn’s official ranking: https://hubs.ly/Q03gk-rK0 #LinkedInTopCompanies

We are thrilled to announce that Evotec will be 𝗽𝗿𝗲𝘀𝗲𝗻𝘁𝗶𝗻𝗴 𝗼𝘂𝗿 𝗹𝗮𝘁𝗲𝘀𝘁 𝗮𝗱𝘃𝗮𝗻𝗰𝗲𝗺𝗲𝗻𝘁𝘀 𝗶𝗻 𝙞𝙣 𝙫𝙞𝙫𝙤 𝗺𝗼𝗱𝗲𝗹𝘀 at the #AACR25 conference! Our poster, titled "Humanized Mice Models for Immune-Oncology Studies", showcases the innovative capabilities of our huPBMC and huCD34+ mice models. These models are pivotal for evaluating new therapeutic agents, providing a more relevant immune context 𝘪𝘯 𝘷𝘪𝘷𝘰. 𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀: • HuPBMC Mice: Exclusively T-cell lineage, resistant to GvHD, ideal for testing therapeutics requiring effector T-cell function. • HuCD34+ Mice: Multilineage immune population, applicable for assessing immunomodulatory agents and immune checkpoint therapies. Join us at AACR 2025, 𝗯𝗼𝗼𝘁𝗵 # 𝟮𝟱𝟰𝟮 to explore how our humanized mice models can accelerate your research and development in immune-oncology. Don't miss the opportunity to connect with our experts and learn more about our cutting-edge capabilities! 𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲 𝗼𝗿 𝗯𝗼𝗼𝗸 𝗮 𝗺𝗲𝗲𝘁𝗶𝗻𝗴- https://hubs.ly/Q03fVWfS0 #AACR #invivoModels #Oncology #ImmunoOncology

Unlocking Quality by Design: DoE Approach Applied to TSWG Technology Curious about the application of Design of Experiments in Twin Screw Wet Granulation? Join Maria Dorly Del Curto in the final episode of our "Mastering Quality by Design" webinar series as she showcases a case study demonstrating DoE's importance in drug formulation. Are you ready to elevate your formulation strategies? https://hubs.ly/Q03c4Hyr0 Dive into this essential topic and access the entire "Mastering Quality by Design" series on demand now.

Evotec is gearing up for ESCMID Global 2025 As a leader in infectious disease research, our team is driving innovation in antibacterial, antifungal, antituberculosis, and antiviral drug discovery. Visit us at Booth I40 to explore our cutting-edge platforms and discover how we can accelerate your projects. Join our poster presentations to gain insights into our latest advancements in anti-infective R&D. Don't miss this opportunity to connect with our experts and discuss groundbreaking solutions to create new therapeutics. See you in Vienna! Request a download of our scientific posters- https://hubs.ly/Q03cG-v_0 #ESCMID2025 #InfectiousDiseases #DrugDiscovery

Only one week until our webinar on leveraging locked nucleic acid chemistry to enhance oligonucleotide characterization! Join us on 9 April to discover advanced pharmacokinetic models and screening strategies that optimize ASO design straight from industry experts. Register now to elevate your oligonucleotide drug discovery approach. https://hubs.ly/Q03f38LL0 #Oligonucleotides #Oligo #LNA #ASO #DrugDiscovery #ASOBasedDrugs #OligonucleotideTherapeutics

We feel honored to have been selected as a winner in the #biologics category of Outsourced Pharma’s CDMO Leadership Awards 2025. Jon Gunther, VP Business Development, took part in the celebration in New York and was thrilled to receive the award. A big thank you to our customers who made this win possible! Learn more about the event here- https://hubs.ly/Q03f2W-k0 #biotherapeutics #biomanufacturing

Exciting innovations are shaping the future of drug development, and Evotec's Carleen Kluger has shared her expertise in The Medicine Maker’s latest piece on next-generation sequencing (NGS) and multi-omics technologies in answer to this question "Looking ahead to the next 5–10 years, what will be the key disruptors and/or what can be improved upon in the pharma industry". In an era where precision medicine and data-driven insights are revolutionizing the industry, Carleen’s perspective highlights the critical role these technologies play in accelerating drug discovery and development. Read the full article here: https://hubs.ly/Q03f2-yd0 Let’s discuss—how do you see multi-omics shaping the future of medicine? Contact us at info@evotec.com #PanOmics #MultiOmics #NGS

Join the Evotec team at the 𝗖𝗲𝗹𝗹 & 𝗚𝗲𝗻𝗲 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 𝗼𝗻 𝘁𝗵𝗲 𝗠𝗲𝗱 𝟮𝟬𝟮𝟱! We're looking forward to connect with industry leaders and innovators in the beautiful setting of Rome. Our SVP, Head of Cell Therapy Business Development, Bernd Muehlenweg, will be presenting 𝗘𝘃𝗼𝘁𝗲𝗰'𝘀 𝗮𝗰𝘁𝗶𝘃𝗶𝘁𝗶𝗲𝘀 𝗮𝗻𝗱 𝗮𝗱𝘃𝗮𝗻𝗰𝗲𝗺𝗲𝗻𝘁𝘀 𝗶𝗻 𝘁𝗵𝗲 𝗰𝗲𝗹𝗹 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝘀𝗽𝗮𝗰𝗲 on Tuesday, 15 April at 5 PM CET. Additionally, we'll have a booth in the exhibit hall for more in-depth discussions. Don't miss this opportunity to discuss how Evotec can help you accelerate your cell therapy development. 𝗥𝗲𝗮𝗰𝗵 𝗼𝘂𝘁 𝘁𝗼 𝘀𝗰𝗵𝗲𝗱𝘂𝗹𝗲 𝗮 𝗺𝗲𝗲𝘁𝗶𝗻𝗴 𝘄𝗶𝘁𝗵 𝘂𝘀 𝗮𝗻𝗱 𝗹𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲 𝗮𝗯𝗼𝘂𝘁 𝗼𝘂𝗿 𝗽𝗿𝗲𝘀𝗲𝗻𝗰𝗲 𝗮𝘁 𝘁𝗵𝗲 𝗲𝘃𝗲𝗻𝘁 https://hubs.ly/Q03f4DQV0 #iPSC #Celltherapy #CGMed25 Irving Donadon, PhD, MBA; Bernd Muehlenweg; Silvia Aldi